Status:
RECRUITING
Chemoradiotherapy Versus Biomarker-Guided Therapy for Elderly and Frail GBM Patients
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Glioblastoma Multiforme
Eligibility:
MALE
65+ years
Phase:
PHASE2
Brief Summary
Currently, the optimal treatment regimen for elderly Glioblastoma (GBM) patients with poor performance status (PS) is unknown. Based on data for elderly GBM patients and the limited data for patients ...
Eligibility Criteria
Inclusion
- Newly-diagnosed, histologically proven, intracranial glioblastoma with maximal safe resection. Biopsy alone is expected if resection is not possible. MGMT promoter methylation status must be tested for all patients.
- History and physical examination, including neurological examination, within 14 days prior to randomization.
- Age ≥ 65 \& KPS of 60 - 70
- Stable or decreasing dose of corticosteroids for at least 14 days prior to randomization.
- Laboratory evaluation within 7 days prior to randomization, with adequate function as defined below:
- ANC ≥ 1.5 x 109/L
- Platelets ≥ 100 x 109/L
- Estimated Glomerular Filtration Rate (eGFR) \> 59
- Total serum bilirubin ≤ 30 umol/L (ie ≤ 1.5 times ULN)
- ALT \< 150 U/L (ie \< 3 times ULN)
- AST \< 120 U/L (ie \< 3 times ULN)
- Alkaline phosphatase \< 390 U/L (ie \< 3 times ULN)
- Patients must sign a study-specific informed consent prior to study registration.
- Patients of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period and for a period of 6 months after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
- Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
- This will apply for male patients only and their female partner if of child bearing potential.
- Effective contraception should also be used by male patients taking temozolomide. Men being treated with temozolomide are advised not to father a child during or up to 6 months after discontinuation of treatment (male patients).
- Male patients should agree to not donate sperm during the study treatment and for six months post treatment completion.
Exclusion
- Recurrent malignant gliomas
- Prior invasive malignancy (except for non-melanomatous skin cancer) unless disease free for ≥ 3 years.
- Prior head or neck RT (except for T1 glottic cancer), or systemic therapy precluding delivery of concurrent and adjuvant temozolomide
- Treatment with any other therapeutic clinical protocol within 30 days prior to study registration or during participation in the study.
- Severe, active co-morbidity, defined as follows:
- Unstable angina and/or congestive heart failure requiring hospitalization
- Transmural myocardial infarction within the last 6 months
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study registration
- Any severe, active co-morbidity precluding delivery of temozolomide.
- History of hypersensitivity reaction to temozolomide components or to dacarbazine.
- Active HBV infection
Key Trial Info
Start Date :
July 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2032
Estimated Enrollment :
121 Patients enrolled
Trial Details
Trial ID
NCT04765514
Start Date
July 27 2022
End Date
June 1 2032
Last Update
June 12 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tom Baker Cancer Centre
Calgary, Alberta, Canada
2
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2